3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Lymphoma, T-Cell, Cutaneous
7
Lymphoma
7
Sezary Syndrome
5
Immunoblastic Lymphadenopathy
5
Recurrence
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Mycosis Fungoides
4
Melanoma
4
Lymphoma, Non-Hodgkin
4
Lymphoma, Large-Cell, Anaplastic
4
Lymphoma, Large B-Cell, Diffuse
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Subcutaneous panniculitis-like T-cell lymphoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, Mantle-Cell
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, Follicular
3
Lymphoma, B-Cell, Marginal Zone
3
Hodgkin Disease
3
Burkitt Lymphoma
3
Waldenstrom Macroglobulinemia
2
Skin Neoplasms
2
Primary Myelofibrosis
2
Neoplasms, Plasma Cell
2
Myeloproliferative Disorders
2
Multiple Myeloma
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, T-Cell
2
Lymphoma, Extranodal NK-T-Cell
2
Leukemia, Myelomonocytic, Chronic
2
Interventions
cemiplimab
3
Transdermal Patch
1
Sirolimus
1
Prednisone
1
Everolimus
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cutaneous Squamous Cell Carcinoma
×
Prednisone
×
Dermatologic
×
Clear all
NCT04339062
2025-04-23
CONTRAC
Dana-Farber Cancer Institute
Phase 1/2
Completed
12 enrolled
13 charts